S. Ren

Repurposing azacitidine and carboplatin to prime for anti-PDL1 re-challenge of immunotherapy-resistant melanoma

M. Lyle, R. Vilain, N. Bowden, 2022, medRxiv.

Repurposing Azacitidine and Carboplatin to Prime Immune Checkpoint Blockade–resistant Melanoma for Anti-PD-L1 Rechallenge

J. Wong, R. Vilain, N. Bowden, 2022, Cancer research communications.

Abstract 5555: Discovery of DN-016: A highly potent, selective and orally available IDO1 inhibitor for treating cancers

Donghai Li, X. Ye, Tao Chen, 2018, Clinical Research (Excluding Clinical Trials).